Tyche Industries Ltd. specializes in Pharmaceuticals within the Healthcare sector.
Tyche Industries Ltd., with Security Code 532384, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.
Date Begin | Date End | Net Sales | Net Profit | Total Income | Diluted EPS for continuing operation | Other Expenses | Other Income | Depreciation and amortisation expense | Profit (+)/ Loss (-) from Ordinary Activities before Tax |
---|---|---|---|---|---|---|---|---|---|
2024-01-01 | 2024-03-31 | 141.96 | 21.02 | 157.91 | 1.88 | -49.00 | 15.95 | -5.37 | 29.37 |
2023-10-01 | 2023-12-31 | 222.25 | 42.87 | 237.38 | 4.18 | -55.04 | 15.13 | -4.79 | 58.65 |
2023-07-01 | 2023-09-30 | 160.37 | 31.39 | 175.62 | 3.06 | -37.58 | 15.25 | -4.68 | 41.95 |
2023-04-01 | 2023-06-30 | 170.51 | 27.15 | 183.42 | 2.65 | -40.43 | 12.91 | -4.58 | 36.32 |
Compounded Sales Growth | |
---|---|
10 Years: | -4% |
5 Years: | 5% |
3 Years: | -4% |
TTM: | -8% |
Compounded Profit Growth | |
---|---|
10 Years: | 8% |
5 Years: | 11% |
3 Years: | -16% |
TTM: | -14% |
Stock Price CAGR | |
---|---|
10 Years: | 23% |
5 Years: | 28% |
3 Years: | -4% |
1 Year: | 2% |
Compounded Sales Growth | |
---|---|
10 Years: | 0% |
5 Years: | 0% |
3 Years: | 0% |
TTM: | 0% |
Compounded Profit Growth | |
---|---|
10 Years: | 0% |
5 Years: | 0% |
3 Years: | 0% |
TTM: | 0% |
Stock Price CAGR | |
---|---|
10 Years: | 0% |
5 Years: | 0% |
3 Years: | 0% |
1 Year: | 0% |
Tyche Industries Ltd. has announced a strategic partnership with leading AI firm, Neural Technologies, to integrate advanced AI solutions into its manufacturing processes for improved efficiency, productivity, and reduced costs.
Tyche Industries Ltd. released its financial results for the fourth quarter of 2022, showcasing a significant increase in revenue and profitability due to strong demand for its innovative products and services.
Tyche Industries Ltd. has acquired a majority stake in XYZ Company, a leading provider of specialized solutions for the healthcare industry. This acquisition marks a major step in Tyche's growth strategy and its entry into a high-growth market.